Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
54 Results for "
Fluconazole
" in MedChemExpress (MCE) Product Catalog:
Products (54)
54 Results for "Fluconazole" in MCE Product Catalog:
Cat. No.: HY-138074
CAS No.: 93074-04-5
Synonyms: 5-Ketomilbemycin A4 oxime; 5-Oxomilbemycin A4 5-oxime
Milbemycin A4 oxime (5-Ketomilbemycin A4 oxime; 5-Oxomilbemycin A4 5-oxime) is a derivative of Milbemycin A4 (HY-126906) and a component of Milbemycin oxime (HY-B0778), both of which have insecticidal and nematicidal activities. Milbemycin A4 oxime (0.05 mg/kg) reduces the number of microfilariae in naturally infected dogs with D. immitis and inhibits the growth of clinical isolates of Candida glabrata (MIC80=16-32 μg/mL). Milbemycin A4 oxime (2.5 μg/mL) blocks the efflux of Fluconazole (HY-B0101) from clinical isolates of Candida glabrata. Milbemycin A4 oxime enhances doxorubicin-induced cell growth inhibition and increases the intracellular accumulation of doxorubicin and P-glycoprotein substrate Rhodamine 123 (HY-D0816) in doxorubicin-resistant but not sensitive MCF-7 breast cancer cells in a concentration-dependent manner.
Cat. No.: HY-184314
CAS No.: 3122934-62-4
Antifungal agent-166 is an antifungal agent. The combination of Antifungal agent-166 and Fluconazole exerts synergistic bacteriostatic effects against fluconazole-resistant Candida albicans. Antifungal agent-166 exhibits bacteriostatic activity against both Candida glabrata and Cryptococcus neoformans. Antifungal agent-166 reverses the fluconazole resistance of strains by downregulating ergosterol synthesis-related genes, drug resistance-related genes and virulence-related genes. Antifungal agent-166 can enhance the efficacy of Fluconazole in Galleria mellonella and mouse candidiasis models, reduce fungal load and improve survival rate. Antifungal agent-166 can be used in the research of fungal infections .
Cat. No.: HY-136752
CAS No.: 1155361-00-4
CYP51-IN-2 (compound 1b), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows 64 and 128 times higher activity than that of Fluconazole against Microsporum gypseum and Candida albicans, respectively .
Cat. No.: HY-189270
CAS No.: 702697-89-0
Chitin synthase-IN-16 is a competitive Chitin synthase 2 inhibitor with an IC50 of 20.89 μM against CaChs2. Chitin synthase-IN-16 synergistically enhances the activity of Fluconazole (HY-B0101) against Fluconazole-tolerant Candida albicans. Chitin synthase-IN-16 can be used for research on invasive fungal infections .
Cat. No.: HY-186076
CAS No.: 958888-13-6
Hsp90-IN-47 (Compound C15) is a Hsp90 inhibitor and antifungal agent, with an IC50 of 0.014 μM against Hsp90α. When combined with Fluconazole (HY-B0101), Hsp90-IN-47 exerts significant synergistic antifungal effects against fluconazole-resistant Candida albicans 0304103. Hsp90-IN-47 exhibits antitumor activity against acute myeloid leukemia and non-small cell lung cancer .
Cat. No.: HY-136757
CAS No.: 1155361-05-9
CYP51-IN-2 (compound 1g), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively .
Cat. No.: HY-187652
CAS No.: 2883514-82-5
Synonyms: CMLD012336
Azoffluxin (CMLD012336) is a Cdr1 inhibitor. Azoffluxin enhances the activity of Fluconazole (HY-B0101) and other intracellular-acting antifungal agents against drug-resistant Candida. Azoffluxin is used for research on fungal efflux-mediated azole resistance and combined antifungal therapy .
Cat. No.: HY-187518
CAS No.: 3134912-65-2
Target:
Research Areas:
NMT-IN-9 is an arylpyrrolidone-based NMT inhibitor with an IC50 of 93.20 nM and a KD of 5.57 × 10 -9 M against NMT. NMT-IN-9 exhibits broad-spectrum antifungal activity against Candida albicans, Candida glabrata, Candida tropicalis, Cryptococcus neoformans and Aspergillus fumigatus, with an MIC of 2-16 μg/mL, and retains activity against fluconazole-resistant Candida isolates, with an MIC of 8-16 μg/mL. NMT-IN-9 induces intracellular ROS accumulation, mitochondrial membrane depolarization, DNA damage, apoptosis and necrotic cell death in fungal cells, and disrupts fungal cell integrity. NMT-IN-9 can be used for studies on NMT-targeted antifungal mechanisms and fluconazole-resistant Candida infections .
Cat. No.: HY-136756
CAS No.: 1155361-04-8
CYP51-IN-2 (compound 1f), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 15.6 ng/mL for Microsporum gypseum and Candida albicans, respectively .
Cat. No.: HY-119726B
Fosmanogepix TFA (APX001 TFA) is an orally active APX001A (HY-18233) prodrug and antifungal agent. Fosmanogepix TFA is effective against Cryptococcus neoformans, Fluconazole (HY-B0101)-resistant C. auris. Fosmanogepix TFA is effective in the treatment of invasive pulmonary aspergillosis and pulmonary murine mucormycosis .
Cat. No.: HY-187118
CAS No.: 174308-47-5
Cat. No.: HY-181404
Target:
Research Areas:
PA36-2 is an Mdr1 inhibitor and azole resistance reversal agent, with a IC50 of 1.0 μg/mL and a Kd of 4.209 μM against Candida albicans Mdr1. By effectively inhibiting the activity of the Mdr1 efflux pump, PA36-2 prevents the pumping of substrates out of cells, enhances the intracellular accumulation of azole antibiotics, and exerts a synergistic effect with antifungal agents such as Fluconazole (FLC) (HY-B0101). PA36-2 can be used in the research of azole-resistant candidiasis .
Cat. No.: HY-184728
Antifungal agent-169 (compound 5p) is an antifungal agent that inhibits fluconazole (HY-B0101)-susceptible Candida albicans SC5314 with an MIC50 of 0.28 μM. Antifungal agent-169 reduces the expression levels of cAMP-PKA pathway-related genes including RAS1, EFG1, BCR1, ECE1 and HWP1 in Candida albicans. Antifungal agent-169 inhibits biofilm formation and hyphal growth of Candida albicans. Antifungal agent-169 can be used in studies related to Candida albicans infection .
Cat. No.: HY-187376
Target:
Research Areas:
CZx-243 is an orally active broad-spectrum antifungal agent. CZx-243 binds to the active site of fungal CYP51 and interferes with ergosterol biosynthesis by depleting ergosterol and causing the accumulation of upstream sterol intermediates. CZx-243 blocks yeast-to-hypha transition; it inhibits the membrane integrity of fungi such as Candida glabrata and Cryptococcus neoformans. CZx-243 significantly reduces renal fungal burden in a systemic mouse model of invasive fungal infection resistant to Fluconazole (HY-B0101). CZx-243 can be used in the research of fungal infections .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
